[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastrointestinal-complication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastrointestinal-complication":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100646451","phase-3-tegoprazan-for-prevention-of-gastrointestinal-complication-in-ischemic-stroke-patients-on-antiplatelet-therapy-tegostroke-100646451",false,"NCT07687706","Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)","A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Superiority, Investigator-initiated Trial of Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)","TegoStroke","Inclusion Criteria:\n\n1. Age 19 years or older.\n2. Hospitalization for acute ischemic stroke or transient ischemic attack, with antiplatelet therapy initiated for the first time, expected to continue for at least 6 months at the treating physician's discretion per relevant stroke guidelines, and within 4 weeks of the first antiplatelet dose at the time of randomization.\n3. Written informed consent provided by the participant or a legally authorized representative.\n4. Ability and willingness to understand the study procedures described in the consent form and to comply with the study protocol.\n\nExclusion Criteria:\n\n1. History of peptic ulcer disease diagnosis or gastrointestinal bleeding within the past year. At screening, the history and findings of any EGD performed within the preceding 2 years were obtained by participant interview.\n2. Need for concomitant anticoagulant therapy (transient anticoagulation such as argatroban during the index admission is permitted, with randomization after it is stopped)\n3. Anticipated difficulty in undergoing gastrointestinal endoscopy during the study period.\n4. Use of a P-CAB, PPI, or H2-receptor antagonist within 1 week before randomization, or an active indication for these agents, a mucosal protectant, or an antacid at enrollment. Temporary use of these agents during acute care in the index admission, since discontinued and without a current indication, is not exclusionary.\n5. Hypersensitivity or contraindication to a P-CAB or to benzimidazoles.\n6. AST, ALT, ALP, or γ-GT ≥5 times the upper limit of normal (ULN), or total bilirubin ≥3 times the ULN at screening.\n7. Participation within the past 12 months in any of the following: (1) a clinical study that may affect the efficacy or safety assessments of the present study; (2) a study involving an investigational product or procedure not administered under standard-of-care guidelines; (3) a study that may pose additional risk to the participant. (Participation in other clinical studies is otherwise permitted.)\n8. Current use of, or use within five half-lives of, a contraindicated interacting drug (atazanavir, nelfinavir, rilpivirine, and preparations containing these components).\n9. Any other condition deemed by the investigators to render the patient unsuitable for study participation, including but not limited to:","ALL","19 Years",{"count":20,"type":21},1524,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Patients with ischemic stroke commonly receive antiplatelet therapy, frequently starting as dual antiplatelet therapy, which is associated with an increased risk of gastrointestinal complications. Although evidence for gastroprotection is established in coronary artery disease, no comparable guidance or evidence exists for stroke care. Tegoprazan is a potassium-competitive acid blocker offering rapid, meal-independent acid suppression with fewer drug interactions than proton pump inhibitors, yet whether it prevents such complications after stroke remains unknown. Thus, the investigators aim to evaluate whether tegoprazan reduces gastrointestinal complications in patients receiving antiplatelet therapy after ischemic stroke.\n\nTegoStroke is a phase 3, multicenter, randomized, double-blind, placebo-controlled, superiority trial conducted at more than 20 centers in the Republic of Korea. Adult patients who are starting antiplatelet therapy after acute ischemic stroke or transient ischemic attack, and who are expected to continue it for at least 6 months, will be included. Eligible patients will be 1:1 randomized to receive oral tegoprazan 50 mg once daily or matching placebo for 180 days. The primary outcome is a composite of upper or indeterminate-origin gastrointestinal bleeding, gastric or duodenal ulcer ≥3 mm, or erosive esophagitis, ascertained up to a day-180 esophagogastroduodenoscopy. This study would provide the first randomized evidence on routine gastroprotection for patients on antiplatelet therapy after ischemic stroke.",[27,28,29,30,31,32],"Ischemic Stroke","Ischemic Stroke, Acute","Transient Ischemic Attack (TIA)","Cerebrovascular Disease","Gastrointestinal Complication","Gastrointestinal Bleeding",[31,34,35,27,36,30],"Gastroprotection","Gastrointestinal Gleeding","Transient Ischemic Attack","RECRUITING","2026-07-07",{"date":40,"type":41},"2026-07-08","ACTUAL",{"date":43,"type":41},"2026-01-26",{"date":45,"type":21},"2027-12",{"name":47,"class":48},"Hanyang University Guri Hospital","OTHER",24,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100521698","the-influence-of-feeding-source-on-the-gut-microbiome-and-time-to-full-feeds-in-neonates-with-congenital-gastrointestinal-pathologies-100521698","NCT06072976","The Influence of Feeding Source on the Gut Microbiome and Time to Full Feeds in Neonates With Congenital Gastrointestinal Pathologies","Inclusion Criteria:\n\n* Infants with gastroschisis, giant omphalocele, intestinal atresia, mid-gut volvulus, hirschsprungs disease.\n\nExclusion Criteria:\n\n1. Infant has already been on feeds\n2. Infants \\\u003C34 weeks gestation\n3. Parents with contraindications to providing milk (i.e. drug use-cocaine, fentanyl, meth BUT oxy\u002Fsuboxone\u002Fmarijuana OK)\n4. Complicated gastroschisis\n5. Short gut syndrome\n6. Additional congenital anomalies that affect ability to tolerate milk (i.e. cyanotic congenital heart disease BUT kidney disease ok)","0 Days","55 Years",{"count":59,"type":21},116,[61],"NA","This study explores the use of an exclusive human milk diet versus standard feeding practices to compare the influence on feeding outcomes and the gut bacteria in infants with intestinal differences.",[31,64,65,66,67,68],"Intestinal Obstruction","Gastroschisis","Hirschsprung Disease","Omphalocele","Midgut Volvulus","2026-04-28",{"date":71,"type":41},"2026-04-30",{"date":73,"type":41},"2023-06-09",{"date":75,"type":21},"2027-06-09",{"name":77,"class":48},"Seattle Children's Hospital",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":17,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":111},"100350911","collection-and-distribution-of-biospecimens-for-novel-research-uses-100350911","NCT03848962","Collection and Distribution of Biospecimens for Novel Research Uses","iSpecimen Network Protocol: Collection and Distribution of Remnant and Research Use Only Biospecimens for Novel Research Uses","Inclusion Criteria:\n\n* Individual is developmentally aged 7 years old and above for RUO collections (only)\n* Individual meets requirements of a current request for research materials from iSpecimen\n* If a blood collection will be performed as part of the screening process or RUO collection, the individual's health will be assessed by medical staff through medical record review, clinical exam, and\u002For the review of an updated medical history as provided by the participant\n* Individual has reviewed and signed a consent form for an RUO specimen collection if required as part of the research or if a minor or a person with diminished decision-making capacity, their parent\u002Fguardian or Legally Authorized Representative has reviewed and signed the consent form on their behalf.\n* Individual has reviewed and signed a consent form for remnant specimen usage in research if required as part of the research or if a minor or a person with diminished decision-making capacity, their parent\u002Fguardian or Legally Authorized Representative has reviewed and signed the consent form on their behalf\n\nExclusion Criteria:\n\n* Subjects that do not meet the inclusion criteria outlined above.",true,"1 Month","89 Years",{"count":90,"type":21},10000,"OBSERVATIONAL","iSpecimen aims to create a clinical partner network of hospitals, laboratories, academic institutions, and other healthcare organizations (\"institutions\") capable of providing researchers and educators (\"researchers\") with annotated biospecimens for use in biomarker discovery and validation; diagnostic test and instrumentation development and validation; therapeutics development; other medical research including the impact that various specimen collection and handling methods and conditions have on research results; and in education such as researcher or physician training (collectively \"research\").",[94,95,31,96,97,98,99,100],"Cancer","Healthy","Autoimmune Diseases","Infectious Disease","Women's Health: High-Risk Pregnancy","Dermatologic Disease","Blood Disease","2022-11-08",{"date":103,"type":41},"2022-11-09",{"date":105,"type":41},"2016-06-30",{"date":107,"type":21},"2026-12-31",{"name":109,"class":110},"iSpecimen Inc","INDUSTRY",2]